{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=103", "query": { "intervention": "ABI-007(Abraxane)", "page": 103 }, "page_size": 10 }, "pagination": { "page": 103, "page_size": 10, "total_count": 2456, "total_pages": 246, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=104&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=102&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T21:12:40.226Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02333188", "title": "Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of Unknown Primary", "Adult Cholangiocarcinoma", "Gallbladder Carcinoma", "Gastric Adenocarcinoma", "Malignant Gastrointestinal Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma", "Stage III Ampulla of Vater Cancer", "Stage III Pancreatic Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gallbladder Cancer", "Stage IIIB Gastric Cancer", "Stage IV Ampulla of Vater Cancer", "Stage IV Gallbladder Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-12", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 8, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02333188" }, { "nct_id": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cervical Neoplasms", "Endometrial Neoplasms", "Squamous Cell Carcinoma of Head and Neck", "Gallbladder Neoplasms", "Cholangiocarcinoma", "Esophageal Neoplasms", "Triple Negative Breast Neoplasms", "Hepatocellular Carcinoma", "Urinary Bladder Neoplasms", "Ovarian Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "Pembrolizumab/Vibostolimab Co-Formulation", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 611, "start_date": "2021-09-16", "completion_date": "2025-08-05", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 14, "location_summary": "Anchorage, Alaska • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05007106" }, { "nct_id": "NCT03693612", "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "feladilimab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-11-26", "completion_date": "2021-09-16", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03693612" }, { "nct_id": "NCT01649336", "title": "A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "MEK162, MEK inhibitor; oral", "type": "DRUG" }, { "name": "Paclitaxel, mitotic inhibitor; intravenous", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 36, "start_date": "2012-07", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2020-09-14", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Lafayette, Indiana • New York, New York + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01649336" }, { "nct_id": "NCT02608216", "title": "[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasm", "Metastatic Breast Cancer", "Rb+ Breast Cancer" ], "interventions": [ { "name": "[18F]FLT", "type": "DRUG" }, { "name": "PET/CT", "type": "DEVICE" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2015-11", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02608216" }, { "nct_id": "NCT03076216", "title": "A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Unresectable Locally Advanced Pancreatic Carcinoma" ], "interventions": [ { "name": "OncoSil™", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "OncoSil Medical Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2017-08-01", "completion_date": "2020-11-28", "has_results": false, "last_update_posted_date": "2021-07-13", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 4, "location_summary": "Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03076216" }, { "nct_id": "NCT00085501", "title": "S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cetuximab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2004-07", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2012-11-01", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 163, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Berkeley, California + 113 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085501" }, { "nct_id": "NCT06845319", "title": "NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2025-10-20", "completion_date": "2028-10-20", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06845319" }, { "nct_id": "NCT01320592", "title": "PD0332991/Paclitaxel in Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PD0332991", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2011-03", "completion_date": "2019-05", "has_results": false, "last_update_posted_date": "2020-04-08", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01320592" }, { "nct_id": "NCT02794571", "title": "Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Tumors" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2016-05-23", "completion_date": "2024-11-13", "has_results": false, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-11-09T21:12:40.226Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02794571" } ] }